trending Market Intelligence /marketintelligence/en/news-insights/trending/0hjcm4vjprxwoncprlvtcg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Aralez launches allergy drug in Canada

LK Bennett Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Aralez launches allergy drug in Canada

Aralez Pharmaceuticals Inc. announced the commercial launch of Blexten in Canada for the treatment of seasonal allergic rhinitis and chronic spontaneous urticaria.

The drug will be distributed by Tribute Pharmaceuticals Canada Inc., an Aralez subsidiary, and will have eight years of market exclusivity.

According to Aralez, the Canadian antihistamine market is currently valued at approximately C$120 million per year.

Chronic spontaneous urticaria is a disabling skin condition that causes red, swollen, itchy and painful hives. Allergic rhinitis occurs when the immune system overreacts to particles in the air.